US-based Hyperion Biosystems and Colorcon on Tuesday declared a licensing agreement to commercialise and market a jointly-developed, anti-counterfeiting technology for solid oral dosage pharmaceutical and nutraceutical products.
Colorcon is a supplier of film coating systems, modified release technology, specialty excipients and functional packaging for the healthcare industry. Hyperion Biosystems applies its expertise in optical detection, artificial intelligence (AI) and physics-based algorithms to create solutions for authentication, chemical sensing, product aging, tamper evidence and diagnostics for multiple industries.
On-dose authentication is claimed to integrates security measures directly into the dosage form, providing fast product verification and traceability. When products are separated from their original packaging, taggants applied directly within the film coating provides a convenient way for companies to verify whether a product is authentic in markets around the world.
"This agreement is the result of a multi-year relationship between Hyperion Biosystems and Colorcon," said Jason Cox, PhD, Hyperion Biosystems CEO. "Our teams have closely collaborated to create a unique solution for on-dose authentication. By combining our expertise in authentication additives and our core Halo product suite, we are supporting Colorcon's efforts to solve the highly complex and growing challenge of counterfeit pharmaceutical and nutraceutical products in the global market."
"Colorcon is evaluating various ways to add on-dose authentication technology to its SoteriaRx product portfolio to meet the FDA requirements around physical-chemical identifiers (PCID)," said Gary Pond, Colorcon director of Strategic Business Development. "This agreement with Hyperion Biosystems demonstrates our ongoing commitment to customers by offering innovative solutions that will improve security in the pharmaceutical supply chain, seamlessly integrating into existing manufacturing processes and most importantly, safeguarding both patients and trusted brands."
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval